onr:"swepub:oai:DiVA.org:uu-10957"
Search: onr:"swepub:oai:DiVA.org:uu-10957" > Sirolimus therapy a...
- 1 of 1
- Previous record
- Next record
- To hitlist
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation
- Campistol, Josep M. (author)
- Eris, Josette (author)
- Oberbauer, Rainer (author)
- show more...
- Friend, Peter (author)
- Hutchison, Brian (author)
- Morales, J.M. (author)
- Stallone, Giovanni (author)
- Russ, Graeme (author)
- Rostaing, Lionel (author)
- Kreis, Henri (author)
- Burke, James T. (author)
- Brault, Yves (author)
- Scarola, Joseph A. (author)
- Neylan, John F. (author)
- show less...
- (creator_code:org_t)
- 2006
- 2006
- English.
- In: Journal of the American Society of Nephrology. - 1046-6673 .- 1533-3450. ; 17:2, s. 581-589
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Sirolimus (SRL) is a mammalian target of rapamycin inhibitor that, in contrast to cyclosporine (CsA), has been shown to inhibit rather than promote cancers in experimental models. At 3 mo +/- 2 wk after renal transplantation, 430 of 525 enrolled patients were randomly assigned to remain on SRL-CsA-steroids (ST) or to have CsA withdrawn and SRL troughs increased two-fold (SRL-ST). Median times to first skin and nonskin malignancies were compared between treatments using a survival analysis. Mean annualized rates of skin malignancy were calculated, and the relative risk was determined using a Poisson model. Malignancy-free survival rates for nonskin malignancies were compared using Kaplan-Meier estimates and the log-rank test. At 5 yr, the median time to a first skin carcinoma was delayed (491 versus 1126 d; log-rank test, P = 0.007), and the risk for an event was significantly lower with SRL-ST therapy (relative risk SRL-ST to SRL-CsA-ST 0.346; 95% confidence interval 0.227 to 0.526; P < 0.001, intention-to-treat analysis). The relative risks for both basal and squamous cell carcinomas were significantly reduced. Kaplan-Meier estimates of nonskin cancer were 9.6 versus 4.0% (SRL-CsA-ST versus SRL-ST; P = 0.032, intention-to-treat analysis). Nonskin cancers included those of the lung, larynx, oropharynx, kidney, gastrointestinal tract, prostate, breast, thyroid, and cervix as well as glioma, liposarcoma, astrocytoma, leukemia, lymphoma, and Kaposi's sarcoma. Patients who received SRL-based, calcineurin inhibitor-free therapy after CsA withdrawal at month 3 had a reduced incidence of both skin and nonskin malignancies at 5 yr after renal transplantation compared with those who received SRL therapy combined with CsA. Longer follow-up and additional trials are needed to confirm these promising results.
Keyword
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Journal of the American Society of Nephrology (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Campistol, Josep ...
- Eris, Josette
- Oberbauer, Raine ...
- Friend, Peter
- Hutchison, Brian
- Morales, J.M.
- show more...
- Claesson, Kersti ...
- Stallone, Giovan ...
- Russ, Graeme
- Rostaing, Lionel
- Kreis, Henri
- Burke, James T.
- Brault, Yves
- Scarola, Joseph ...
- Neylan, John F.
- show less...
- Articles in the publication
- Journal of the A ...
- By the university
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
